Literature DB >> 8663395

Two GC boxes (Sp1 sites) are involved in regulation of the activity of the epithelium-specific MUC1 promoter.

A Kovarik1, P J Lu, N Peat, J Morris, J Taylor-Papadimitriou.   

Abstract

In this report, we have analyzed the function of two Sp1 sites present in the epithelium-specific MUC1 promoter. Using promoter-reporter gene (CAT) constructs, we found that mutagenesis of either of the Sp1 binding motifs at -576/-568 and -99/-90, reduced transcription in MUC1-expressing epithelial cell lines. However, abolition of the binding site at -99/-91 by mutagenesis also resulted in increased transcriptional activity in non-epithelial cell lines, suggesting involvement of the site in tissue-specific expression. In vitro binding assays revealed a novel binding motif at -101/-89 (AGGGGGCGGGGTT), which overlaps but differs from the Sp1 consensus motif by having an adenine residue in the 5'-flanking sequence. The 5'-flanking sequence appeared to be important for binding of an Sp1-unrelated factor (SpA) but not for binding of Sp1. Site-directed mutagenesis of the motif into a site able to bind Sp1, but unable to bind SpA, resulted in an increased level of transcription of the CAT reporter gene in all cell lines tested, suggesting a repressive effect of the novel factor on transcription. The ratio between the Sp1 and SpA binding activity in nuclear extracts correlated with both promoter activity and the levels of endogenous transcription in different breast cancer cell lines. Our results are consistent with the idea that the relative activities of the two factors may be involved in the up-regulation of expression of the MUC1 gene seen in breast and other carcinomas.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8663395     DOI: 10.1074/jbc.271.30.18140

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  18 in total

Review 1.  Mucins and blastocyst attachment.

Authors:  Amantha Thathiah; Daniel D Carson
Journal:  Rev Endocr Metab Disord       Date:  2002-05       Impact factor: 6.514

2.  Sp1 and Sp3 control constitutive expression of the human NHE2 promoter by interactions with the proximal promoter and the transcription initiation site.

Authors:  Ian Pearse; Ying X Zhu; Eleanor J Murray; Pradeep K Dudeja; Krishnamurthy Ramaswamy; Jaleh Malakooti
Journal:  Biochem J       Date:  2007-10-01       Impact factor: 3.857

3.  Identification and characterization of the MUC2 (human intestinal mucin) gene 5'-flanking region: promoter activity in cultured cells.

Authors:  J R Gum; J W Hicks; Y S Kim
Journal:  Biochem J       Date:  1997-07-01       Impact factor: 3.857

Review 4.  Cellular and molecular biology of airway mucins.

Authors:  Erik P Lillehoj; Kosuke Kato; Wenju Lu; Kwang C Kim
Journal:  Int Rev Cell Mol Biol       Date:  2013       Impact factor: 6.813

Review 5.  Molecular chemotherapy for breast cancer.

Authors:  A Patterson; A L Harris
Journal:  Drugs Aging       Date:  1999-02       Impact factor: 3.923

6.  Sequence of the 5'-flanking region and promoter activity of the human mucin gene MUC5B in different phenotypes of colon cancer cells.

Authors:  I Van Seuningen; M Perrais; P Pigny; N Porchet; J P Aubert
Journal:  Biochem J       Date:  2000-06-15       Impact factor: 3.857

7.  Cloning and characterization of the 5' flanking region of the sialomucin complex/rat Muc4 gene: promoter activity in cultured cells.

Authors:  S A Price-Schiavi; A Perez; R Barco; K L Carraway
Journal:  Biochem J       Date:  2000-07-15       Impact factor: 3.857

8.  Androgen-dependent regulation of human MUC1 mucin expression.

Authors:  Stephen Mitchell; Paul Abel; Sanjeev Madaan; James Jeffs; Khurram Chaudhary; Gordon Stamp; El-Nasir Lalani
Journal:  Neoplasia       Date:  2002 Jan-Feb       Impact factor: 5.715

9.  Increased expression of colonic Wnt9A through Sp1-mediated transcriptional effects involving arylsulfatase B, chondroitin 4-sulfate, and galectin-3.

Authors:  Sumit Bhattacharyya; Leo Feferman; Joanne K Tobacman
Journal:  J Biol Chem       Date:  2014-04-28       Impact factor: 5.157

Review 10.  Adenoviral vectors for prodrug activation-based gene therapy for cancer.

Authors:  Joshua C Doloff; David J Waxman
Journal:  Anticancer Agents Med Chem       Date:  2014-01       Impact factor: 2.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.